ReviewNPJ precision oncology2025
HER2 expression in breast cancer: evidence gaps and challenges.
Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Expression of HER2 Ultralow in Endometrial Carcinoma, High-Grade Serous Ovarian Cancer and Their Metastases.Cancers · 2026Article
- Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality.Molecules (Basel, Switzerland) · 2026Review
- Development and validation of a DYX1C1- and GNAI1-based nomogram for predicting relapse in HER2-positive breast cancer treated with trastuzumab.Translational cancer research · 2026Article
- Inhibition of histone acetyltransferase KAT7 suppresses proliferation and migration of breast cancer cells.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classification of breast cancer (BC) based on HER2 expression is undergoing significant changes. While traditional approaches have focused on HER2-positive and HER2-negative categories, emerging evidence highlights varied therapeutic responses depending on the level of HER2 protein expression. Breast cancers are now immunohistochemically (IHC) scored into five subgroups, which define two primary therapeutic groups: HER2-positive (IHC 2+ amplified and 3 + ) and HER2-negative (IHC 0, 1 + , and 2+ non-amplified). Recent advances, particularly in antibody-drug conjugates (ADCs), have led to further subclassification of HER2-negative BC into HER2-Low and HER2-null (IHC 0). Also, for HER-positive subgroups, a differential response to HER2-targeted therapies is seen. This evolving landscape challenges the traditional use of HER2 as a diagnostic marker and underscores the need for a deeper understanding of HER2 biology. This review addresses these complexities, focusing on the emerging HER2-Low and Ultralow subtypes, and evaluates the distinct therapeutic responses across the spectrum of HER2 expression in different BC subtypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.